These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1428472)

  • 21. Plasma prolactin concentrations and risk of postmenopausal breast cancer.
    Tworoger SS; Eliassen AH; Rosner B; Sluss P; Hankinson SE
    Cancer Res; 2004 Sep; 64(18):6814-9. PubMed ID: 15375001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma prolactin levels in patients with breast cancer.
    Rose DP; Pruitt BT
    Cancer; 1981 Dec; 48(12):2687-91. PubMed ID: 7306924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Permanent alterations induced in plasma prolactin and estrogen receptor concentration in benign and malignant tissue of women who started oral contraceptive use at an early age.
    Olsson H; Lindahl B; Ranstam J; Borg A; Fernö M; Norgren A
    Anticancer Res; 1987; 7(4B):853-6. PubMed ID: 3674773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolactin concentrations in patients with breast cancer.
    Franks S; Ralphs DN; Seagroatt V; Jacobs HS
    Br Med J; 1974 Nov; 4(5940):320-1. PubMed ID: 4434088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating levels of sex steroids and prolactin in premenopausal women and risk of breast cancer.
    Hankinson SE
    Adv Exp Med Biol; 2008; 617():161-9. PubMed ID: 18497040
    [No Abstract]   [Full Text] [Related]  

  • 26. Disordered nocturnal prolactin regulation in women with breast cancer.
    Malarkey WB; Schroeder LL; Stevens VC; James AG; Lanese RR
    Cancer Res; 1977 Dec; 37(12):4650-4. PubMed ID: 922745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolactin levels in populations at risk for breast cancer.
    Hill P; Wynder EL; Kumar H; Helman P; Rona G; Kuno K
    Cancer Res; 1976 Nov; 36(11 Pt 1):4102-6. PubMed ID: 975051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prolactin and human cancer of the breast. I. Levels of correlation].
    Cueto Ladrón de Guevara J; Villalba Moreno J; García Puche JL; Pedraza V
    Rev Esp Oncol; 1985; 32(3):439-58. PubMed ID: 3870536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic and environmental predictors, endogenous hormones and growth factors, and risk of estrogen receptor-positive breast cancer in Japanese women.
    Yoshimoto N; Nishiyama T; Toyama T; Takahashi S; Shiraki N; Sugiura H; Endo Y; Iwasa M; Fujii Y; Yamashita H
    Cancer Sci; 2011 Nov; 102(11):2065-72. PubMed ID: 21790896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma prolactin and breast cancer risk: a meta- analysis.
    Wang M; Wu X; Chai F; Zhang Y; Jiang J
    Sci Rep; 2016 May; 6():25998. PubMed ID: 27184120
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development.
    Tworoger SS; Eliassen AH; Zhang X; Qian J; Sluss PM; Rosner BA; Hankinson SE
    Cancer Res; 2013 Aug; 73(15):4810-9. PubMed ID: 23783576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum prolactin levels and their relationship to survival in women with operable breast cancer.
    Wang DY; Stepniewska KA; Allen DS; Fentiman IS; Bulbrook RD; Kwa HG; De Stavola BL; Reed MJ
    J Clin Epidemiol; 1995 Jul; 48(7):959-68. PubMed ID: 7782804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors for breast cancer in women undergoing mammography.
    Reuter KL; Baker SP; Krolikowski FJ
    AJR Am J Roentgenol; 1992 Feb; 158(2):273-8. PubMed ID: 1729780
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alcohol and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status: a prospective cohort study.
    Suzuki R; Ye W; Rylander-Rudqvist T; Saji S; Colditz GA; Wolk A
    J Natl Cancer Inst; 2005 Nov; 97(21):1601-8. PubMed ID: 16264180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study.
    Harvie M; Howell A; Vierkant RA; Kumar N; Cerhan JR; Kelemen LE; Folsom AR; Sellers TA
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):656-61. PubMed ID: 15767346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Moderate-vigorous recreational physical activity and breast cancer risk, stratified by menopause status: a systematic review and meta-analysis.
    Neilson HK; Farris MS; Stone CR; Vaska MM; Brenner DR; Friedenreich CM
    Menopause; 2017 Mar; 24(3):322-344. PubMed ID: 27779567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of reserpine on prolactin levels and incidence of breast cancer in postmenopausal women.
    Ross RK; Paganini-Hill A; Krailo MD; Gerkins VR; Henderson BE; Pike MC
    Cancer Res; 1984 Jul; 44(7):3106-8. PubMed ID: 6722826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endogenous sex hormones, prolactin and mammographic density in postmenopausal Norwegian women.
    Bremnes Y; Ursin G; Bjurstam N; Rinaldi S; Kaaks R; Gram IT
    Int J Cancer; 2007 Dec; 121(11):2506-11. PubMed ID: 17657735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adult weight change and risk of postmenopausal breast cancer.
    Eliassen AH; Colditz GA; Rosner B; Willett WC; Hankinson SE
    JAMA; 2006 Jul; 296(2):193-201. PubMed ID: 16835425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer.
    Faupel-Badger JM; Prindiville SA; Venzon D; Vonderhaar BK; Zujewski JA; Eng-Wong J
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1153-8. PubMed ID: 16775175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.